BOSTON SCIENTIFIC CORP — Form 8-K
Filed July 29, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Boston Scientific reported Q2 2026 net sales of $5.442 billion (7.5% reported, 7.0% organic growth), exceeding its 5.5-7.5% guidance range. GAAP EPS of $0.61 and adjusted EPS of $0.86 (vs. guidance $0.82-$0.84). Key development: $1.5 billion investment in MiRus LLC for ~34% equity stake and exclusive option to acquire MiRus's TAVR business. Company completed $2 billion share repurchase (40 million shares). FY 2026 guidance narrowed to 5.5-6.5% organic growth; Q3 guided 3-5% organic growth.
Why this rating
Solid operational beat on revenue/EPS vs. guidance; routine quarterly results. $1.5B MiRus investment is <1% of market cap ($158.7B), meaningful strategic but not transformational. Q3 deceleration flagged.
See more from July 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.